Dr. Jonathan M. Green selected as CEO of the NIH Clinical Center

The NIH Clinical Center is the largest research hospital in the world. The institutional report frames the development in practical terms and ties it to the broader mission or observing effort.

That matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. In announcing the selection, NIH Director Jay Bhattacharya, M. D, Ph. D, said, "Dr. Green's leadership in strengthening NIH’s human research protection program, combined with his experience as a researcher and training in pulmonary and critical care, uniquely.

Under his direction, we will fully realize its potential as both a place of hope for patients through groundbreaking clinical trials and a state-of-the-art engine for NIH. Green will oversee the Clinical Center’s nearly $700 million annual operating budget and the day-to-day operations and management of the 200-bed, 870, 000-square-foot research.

Last year, the Clinical Center had over 3, 000 inpatient admissions and nearly 72, 000 outpatient visits. Green joined NIH in 2018 to serve as director of the NIH Office of Human Subjects Research Protections.

In that role he led the highly successful reorganization of the human research protection program, consolidating the 12 separate NIH Institute and Center-specific Institutional. There, he conducted research on the molecular mechanisms of T cell activation, focusing on the CD28 costimulatory family of receptors.

The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.

Green continues to serve as an attending physician in the Medical Intensive Care Unit and Pulmonary Consult Service at the NIH Clinical Center, and he maintains a long-standing. Aiyelawo, who has effectively led the NIH Clinical Center as its Acting CEO since 2025,” said Dr.

Because the account originates with NIH News Releases, it functions best as a primary institutional report that is close to the data and operations, not as independent scientific validation. Institutional communications are produced by organizations with legitimate interests in presenting their work in a favorable light, which does not make them unreliable but does make them partial. Details that complicate the narrative, including instrument limitations, unexpected failures and results below projections, tend to be minimized relative to progress messages. Technical documentation and peer-reviewed publications, where they exist, provide the complementary layer that institutional releases cannot substitute.

The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Source